Qiagen Looks to Acquire Cellestis to Enhance Portfolio of Molecular Tests in Infectious Disease
April 06, 2011
Qiagen Looks to Acquire Cellestis to Enhance Portfolio of Molecular Tests in Infectious Disease
With the help of QuantiFeron tests in the first-line setting, Qiagen is hoping to improve the capabilities of its DNA and RNA diagnostics in preventing and profiling disease and delivering personalized care.
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- Qiagen, Max Planck Developing qPCR-Based Test for Active TB Risk in Latently Infected Patients
January 12, 2012 / PCR Insider - UPDATE: Qiagen Q2 Revenues Bounce 9 Percent; Plans to Buy Back $100M in Shares
July 25, 2012 / GenomeWeb Daily News - Dx Focus: Japan Approves Qiagen's Therascreen EGFR kit; NIST Releases CMV Standard Reference
January 12, 2012 / PCR Insider - Qiagen Teams with Max Planck on TB MDx Test
January 9, 2012 / GenomeWeb Daily News - BioHelix Gets FDA Nod for First Point-of-Care MDx Test
October 20, 2011 / PCR Insider